Low interferon-gamma release in response to phytohemagglutinin predicts the high severity of diseases.
APACHE
Adolescent
Adult
Aged
Aged, 80 and over
Area Under Curve
Biomarkers
/ blood
Blood Sedimentation
C-Reactive Protein
/ analysis
Female
Humans
Intensive Care Units
Interferon-gamma
/ blood
Lymphocyte Count
Male
Middle Aged
Mitogens
/ administration & dosage
Nervous System Diseases
/ blood
Phytohemagglutinins
/ administration & dosage
Pneumonia
/ blood
Predictive Value of Tests
Procalcitonin
/ blood
Respiratory Tract Diseases
/ blood
Retrospective Studies
Young Adult
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
entrez:
31
5
2019
pubmed:
31
5
2019
medline:
8
6
2019
Statut:
ppublish
Résumé
A clinically useful immune biomarker could potentially assist clinicians in their decision making. We stimulated T-cell proliferation to secret interferon gamma (IFN-γ) by phytohemagglutinin, and then measured the production of IFN-γ (mitogen value [M value]). We aimed to determine the relationship between the M value, clinical severity, and outcomes of diseases.In all, 484 patients admitted to intensive care units were enrolled in this retrospective study. The Acute Physiology and Chronic Health Evaluation II (APACHE II) scores were collected within the first 24 hours. M value, C-reaction protein (CRP), procalcitonin (PCT), erythrocyte sedimentation rate (ESR), and routine blood tests were analyzed and collected during the study.When APACHE II scores were greater than 15 and M values were less than 6, the hospital mortality rose in a straight line. There was an inverse correlation between APACHE II score and M value (rs = -0.212, P < .001). There was a positive correlation between M value and lymphocyte numbers (b' = 0.249, P < .001); however, there was an inverse correlation between M value and WBC (b' = -0.230, P < .001), and ESR (b' = -0.100, P = .029). Neurological diseases had the greatest influence on APACHE II scores (b' = 10.356, P < .001), whereas respiratory diseases had the greatest influence on M value (b' = 1.933, P < .001). Furthermore, in the respiratory system, severe pneumonia had a greater influence on M value. Taking the APACHE II score as the gold standard, the area under the curve of M was 0.632 (95% confidence interval [CI] 0.575-0.690, P < .001), PCT was 0.647 (95% CI 0.589-0.705, P < .001), CRP was 0.570 (95% CI 0.511-0.629, P = .022), and ESR was 0.553 (95% CI 0.494-0.612, P = .078). Divided by M value = 5, the positive predictive value of the M value is 37.22% (115/309) and negative predictive value is 75.43% (132/175).The results show that the M values, PCT, and CRP were better than ESR to predict the severity of diseases. The number and proportion of lymphocytes also affected the result of the M value. To a certain extent, the M value may be a clinically useful immune biomarker, which may help clinicians objectively evaluate the severity of diseases, especially in the respiratory system.
Identifiants
pubmed: 31145331
doi: 10.1097/MD.0000000000015843
pii: 00005792-201905310-00061
pmc: PMC6709005
doi:
Substances chimiques
Biomarkers
0
Mitogens
0
Phytohemagglutinins
0
Procalcitonin
0
Interferon-gamma
82115-62-6
C-Reactive Protein
9007-41-4
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15843Références
PLoS One. 2015 May 11;10(5):e0125794
pubmed: 25961292
Vascular. 2016 Aug;24(4):390-403
pubmed: 26482428
Acta Med Acad. 2016 Nov;45(2):97-103
pubmed: 28000485
Cell Mol Immunol. 2012 Sep;9(5):375-9
pubmed: 22659733
Proc Biol Sci. 2015 Dec 22;282(1821):20143085
pubmed: 26702035
J Immunol. 2016 Nov 1;197(9):3431-3436
pubmed: 27824589
J Immunol. 2002 Oct 15;169(8):4183-9
pubmed: 12370347
Infection. 2014 Dec;42(6):1023-32
pubmed: 25263811
Sci Rep. 2017 Nov 10;7(1):15249
pubmed: 29127315
Rev Esp Quimioter. 2018 Aug;31(4):316-322
pubmed: 29953174
Int J Clin Exp Pathol. 2013 Nov 15;6(12):2668-74
pubmed: 24294353
Clin Chim Acta. 2014 Mar 20;430:79-83
pubmed: 24389051
Anaesthesiol Intensive Ther. 2014 Jan-Mar;46(1):46-9
pubmed: 24643928
Clin Microbiol Infect. 2015 May;21(5):474-81
pubmed: 25726038
Aging Clin Exp Res. 2018 Jun;30(6):555-562
pubmed: 28856612
WMJ. ;115(6):317-21
pubmed: 29094869
Cell Mol Immunol. 2015 Sep;12(5):519-20
pubmed: 26277895
J Mol Cell Biol. 2013 Apr;5(2):143-6
pubmed: 23362310
J Immunol. 2004 May 1;172(9):5213-21
pubmed: 15100259
J Interferon Cytokine Res. 2015 Dec;35(12):969-80
pubmed: 26309018
N Engl J Med. 2013 Aug 8;369(6):529-39
pubmed: 23924003
J Leukoc Biol. 2014 Nov;96(5):767-77
pubmed: 24791959
Int J Tuberc Lung Dis. 2016 Mar;20(3):295-303
pubmed: 27046708
Ann Transl Med. 2016 Mar;4(5):91
pubmed: 27047950
Ann Transl Med. 2016 Mar;4(6):111
pubmed: 27127764
Immunol Cell Biol. 2015 Mar;93(3):226-32
pubmed: 25666097
Cell Immunol. 2017 Mar;313:25-31
pubmed: 28063598